fibroblast activation protein inhibitor (University of Sydney)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namefibroblast activation protein inhibitor (University of Sydney)
Drug Alias Namemetabolic syndrome therapy targeting FAP (University of Sydney)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsGlucose Intolerance
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of Sydney
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity of Sydney
Active IndicationsN/A
Inactive IndicationsGlucose Intolerance

Other Information

ATC CodeN/A
Related LinksN/A